CVS Health stock gains 3.47 percent as vaccine access expands

Published on 10/07/2026 at 16:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock gained 3.47 percent on October 7 as MMR vaccine access expanded across New York. Second-quarter revenue reached USD 106.10 billion.

Schwarzweiß-Reportagefoto eines Apothekers beim Befüllen von Rezeptmedikamenten an der Theke — CVS Health Corp. dokumentiert Schwarzweiß-Reportage eines Apothekers bei der Rezeptabgabe, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health stock gained 3.47 percent on October 7, 2026, with the shares trading at USD 89.43 on the NYSE at 10:54 a.m. ET. The company highlighted MMR vaccination access across New York as the state responds to a measles outbreak.

Vaccine access expands in New York

As Morningstar carried the CVS Health release dated October 7, 2026, eligible patients can receive MMR vaccinations at more than 530 CVS Pharmacy locations across New York. MinuteClinic locations also offer vaccination services, including the recommended second dose for children ages 4 to 6.

The operating message gives CVS a direct role in preventive care while the stock trades below its 52-week high. CVS Health has approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care clinics, approximately 87 million pharmacy benefit members and an estimated 37 million health insurance customers, according to the same October 7 release from Morningstar.

Quarterly earnings set the benchmark

In the second quarter of 2026, CVS Health generated USD 106.10 billion in revenue, up 7.3 percent year over year, while adjusted EPS rose to USD 2.58 from USD 1.81. The figures were reported by MarketBeat in its October 6, 2026 review.

Management set full-year 2026 adjusted EPS guidance at USD 7.90-8.10, compared with the earlier USD 7.30-7.50 range. The comparison matters because the guidance midpoint increased by USD 0.60, while the medical-cost outlook remains central to the Health Care Benefits segment.

Analysts weigh upside against risk

The consensus cited by MarketBeat is Moderate Buy, based on 23 analysts, including 22 Buy ratings and one Hold rating, with an average 12-month target of USD 107.24. The target stands USD 17.81 above the October 7 price, a 19.9 percent premium.

Bank of America analyst Allen Lutz lowered the target from USD 120 to USD 110 on October 6, 2026, while retaining a Buy rating, according to Markets Insider. The note identified potential 340B program changes as a profit headwind and estimated total EPS risk of USD 0.45.

CVS Health stock trades below its high

CVS Health stock was last at USD 89.43 on the NYSE on October 7, 2026 at 10:54 a.m. ET, with a market capitalization of USD 114.1 billion. The price sits 19.2 percent below the 52-week high of USD 110.68 and above the 52-week low of USD 69.51.